Short-term Effects of Empagliflozin on Preventing Contrast Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention, a Randomised Trial

Overview

Journal Sci Rep

Date 2025 Jan 31

PMID 39890841

Authors

Zeinab Sadat Hosseini

Mohammad Javad Jamili

Behzad Ensan

Ghazaleh Donyadideh

Bahram Shahri

Hamid Eshraghi

Susan Darroudi

Mohsen Moohebati

Affiliations

Soon will be listed here.

Abstract

Contrast-induced acute kidney injury (CI-AKI) is a prevalent cause of hospital-acquired renal impairment in patients undergoing intervention. Limited clinical trials explore SGLT2 inhibitors' effects on CI-AKI. This study aimed to assess the short-term effect of empagliflozin- an SGLT2 inhibitor- in reducing CI-AKI incidence in PCI patients regardless of diabetes. This research conducted a double-blind randomized clinical trial involving 121 patients undergoing PCI referred to Ghaem Hospital, Mashhad, Iran from 2022 to 2023. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo, starting one day before PCI and continuing for two days post-procedure. Renal function parameters such as estimated glomerular filtration rate (eGFR), creatinine, cystatin C, and urea were evaluated. After the intervention, empagliflozin users exhibited a significant reduction in mean cystatin C levels compared to the placebo users across all age groups (< 50 years, 50-60 years, and > 60 years). Patients older than 60 showed significant improvements in mean changes of eGFR with empagliflozin. Patients with eGFR > 60 and 45 < eGFR < 60 had a significant increase in eGFR in the empagliflozin group. Mean changes in cystatin C levels were significantly reduced with empagliflozin in all eGFR levels (> 60, 45-60, and < 45). There was no significant difference in urea and creatinine levels between the two groups. Empagliflozin notably decreases CI-AKI incidence in PCI patients by improving renal function parameters such as eGFR and cystatin C. These benefits were observed across various age groups, particularly in middle-aged and elderly, and those with varying renal function levels.

References

Mehran R, Aymong E, Nikolsky E, Lasic Z, Iakovou I, Fahy M . A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44(7):1393-9. DOI: 10.1016/j.jacc.2004.06.068. View

Harjai K, Raizada A, Shenoy C, Sattur S, Orshaw P, Yaeger K . A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol. 2008; 101(6):812-9. DOI: 10.1016/j.amjcard.2007.10.051. View

Gonzalez-Albarran O, Morales C, Perez-Maraver M, Aparicio-Sanchez J, Simo R . Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D. Diabetes Ther. 2022; 13(Suppl 1):35-49. PMC: 9240164. DOI: 10.1007/s13300-022-01276-2. View

Heerspink H, Perco P, Mulder S, Leierer J, Hansen M, Heinzel A . Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019; 62(7):1154-1166. PMC: 6560022. DOI: 10.1007/s00125-019-4859-4. View

Ozkan U, Gurdogan M . The Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarction. Medicina (Kaunas). 2023; 59(3). PMC: 10057721. DOI: 10.3390/medicina59030505. View

Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri S, Torres-Ortiz A, Acharya P . Diagnostics, Risk Factors, Treatment and Outcomes of Acute Kidney Injury in a New Paradigm. J Clin Med. 2020; 9(4). PMC: 7230860. DOI: 10.3390/jcm9041104. View

Paolisso P, Bergamaschi L, Cesaro A, Gallinoro E, Gragnano F, Sardu C . Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry. Diabetes Res Clin Pract. 2023; 202:110766. DOI: 10.1016/j.diabres.2023.110766. View

Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J . Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022; 388(2):117-127. PMC: 7614055. DOI: 10.1056/NEJMoa2204233. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

10.

Feitosa M, Lima E, Abizaid A, Mehran R, Lopes N, de Assis Fischer Ramos T . The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study. Diabetol Metab Syndr. 2023; 15(1):138. PMC: 10291785. DOI: 10.1186/s13098-023-01107-9. View

11.

Lin Y, Huang Y, Hsieh S, Sun J, Chen S, Lin C . Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages. Front Endocrinol (Lausanne). 2019; 10:820. PMC: 6883723. DOI: 10.3389/fendo.2019.00820. View

12.

Abdelrahman A, Awad A, Abdel-Rahman E . Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side. J Clin Med. 2024; 13(4). PMC: 10888733. DOI: 10.3390/jcm13040956. View

13.

Vallon V, Thomson S . The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020; 16(6):317-336. PMC: 7242158. DOI: 10.1038/s41581-020-0256-y. View

14.

Weisbord S, Palevsky P . Contrast-induced acute kidney injury: short- and long-term implications. Semin Nephrol. 2011; 31(3):300-9. PMC: 3143363. DOI: 10.1016/j.semnephrol.2011.05.009. View

15.

Bailey C, Day C, Bellary S . Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr Diab Rep. 2022; 22(1):39-52. PMC: 8888485. DOI: 10.1007/s11892-021-01442-z. View

16.

Tsai K, Chen Y, Chiou T, Chu T, Li L, Ng H . Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants (Basel). 2021; 10(8). PMC: 8388972. DOI: 10.3390/antiox10081166. View

17.

Carbone S, Dixon D . The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2019; 18(1):64. PMC: 6540565. DOI: 10.1186/s12933-019-0869-2. View

18.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

19.

Mohamed D, Khairy E, Saad S, Habib E, Hamouda M . Potential protective effects of Dapagliflozin in gentamicin induced nephrotoxicity rat model via modulation of apoptosis associated miRNAs. Gene. 2019; 707:198-204. DOI: 10.1016/j.gene.2019.05.009. View

20.

Gajewska A, Wasiak J, Sapeda N, Mlynarska E, Rysz J, Franczyk B . SGLT2 Inhibitors in Kidney Diseases-A Narrative Review. Int J Mol Sci. 2024; 25(9). PMC: 11084583. DOI: 10.3390/ijms25094959. View